In a recent study, ARID1A alterations assessed by tissue next-generation sequencing in different cancer types, including NSCLC, were significantly associated with longer PFS after checkpoint blockade, regardless of microsatellite instability or mutational burden, suggesting that the role of this biomarker need to be further explored in clinical setting [206]. The gene discussed is ARID1A; the disease is cancer.